HRP980426A2 - Sulphonamide-substituted compounds, process for their production and their use as medicaments or diagnostics as well as medicaments containing them - Google Patents

Sulphonamide-substituted compounds, process for their production and their use as medicaments or diagnostics as well as medicaments containing them

Info

Publication number: HRP980426A2
Authority: HR; Croatia
Prior art keywords: group; atoms; hydrogen; alkyl; formula
Prior art date: 1997-08-05

Application number

HR19747889.1A

Other languages

English (en)

Croatian (hr)

Inventor

Joachim Brendel

Original Assignee

Hoechst Marion Roussel De Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-05

Filing date

1998-08-03

Publication date

1999-04-30

1997-08-05 Priority claimed from DE19733779A external-priority patent/DE19733779A1/de

1997-10-30 Priority claimed from DE1997147889 external-priority patent/DE19747889A1/de

1998-08-03 Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh

1999-04-30 Publication of HRP980426A2 publication Critical patent/HRP980426A2/hr

Links

150000001875 compounds Chemical class 0.000 title claims description 79
239000003814 drug Substances 0.000 title claims description 32
238000000034 method Methods 0.000 title claims description 20
238000004519 manufacturing process Methods 0.000 title claims description 18
125000004432 carbon atom Chemical group C* 0.000 claims description 122
239000001257 hydrogen Substances 0.000 claims description 117
229910052739 hydrogen Inorganic materials 0.000 claims description 117
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 76
125000000217 alkyl group Chemical group 0.000 claims description 70
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 69
-1 methoxy, sulfamoyl Chemical group 0.000 claims description 58
239000000460 chlorine Substances 0.000 claims description 57
229910052794 bromium Inorganic materials 0.000 claims description 56
229910052801 chlorine Inorganic materials 0.000 claims description 56
229910052731 fluorine Inorganic materials 0.000 claims description 54
150000002431 hydrogen Chemical class 0.000 claims description 48
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
150000003839 salts Chemical class 0.000 claims description 40
125000001424 substituent group Chemical group 0.000 claims description 40
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 38
125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 38
125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 claims description 38
125000000753 cycloalkyl group Chemical group 0.000 claims description 30
125000002947 alkylene group Chemical group 0.000 claims description 24
229940079593 drug Drugs 0.000 claims description 22
238000011321 prophylaxis Methods 0.000 claims description 22
239000000126 substance Substances 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
239000013543 active substance Substances 0.000 claims description 15
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 14
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 14
125000002883 imidazolyl group Chemical group 0.000 claims description 14
125000005936 piperidyl group Chemical group 0.000 claims description 14
125000004076 pyridyl group Chemical group 0.000 claims description 14
125000001544 thienyl group Chemical group 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
206010003119 arrhythmia Diseases 0.000 claims description 11
238000002560 therapeutic procedure Methods 0.000 claims description 11
230000000903 blocking effect Effects 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 10
229940124530 sulfonamide Drugs 0.000 claims description 10
150000003456 sulfonamides Chemical class 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
206010019280 Heart failures Diseases 0.000 claims description 6
125000005956 isoquinolyl group Chemical group 0.000 claims description 6
125000005493 quinolyl group Chemical group 0.000 claims description 6
230000006793 arrhythmia Effects 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
210000002784 stomach Anatomy 0.000 claims description 5
206010003658 Atrial Fibrillation Diseases 0.000 claims description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
206010012735 Diarrhoea Diseases 0.000 claims description 4
102000004257 Potassium Channel Human genes 0.000 claims description 4
208000025865 Ulcer Diseases 0.000 claims description 4
230000036982 action potential Effects 0.000 claims description 4
125000004423 acyloxy group Chemical group 0.000 claims description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
230000002496 gastric effect Effects 0.000 claims description 4
230000000269 nucleophilic effect Effects 0.000 claims description 4
108020001213 potassium channel Proteins 0.000 claims description 4
230000028327 secretion Effects 0.000 claims description 4
231100000397 ulcer Toxicity 0.000 claims description 4
206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
206010042600 Supraventricular arrhythmias Diseases 0.000 claims description 3
206010047281 Ventricular arrhythmia Diseases 0.000 claims description 3
239000002168 alkylating agent Substances 0.000 claims description 3
229940100198 alkylating agent Drugs 0.000 claims description 3
238000005804 alkylation reaction Methods 0.000 claims description 3
230000001746 atrial effect Effects 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
238000007336 electrophilic substitution reaction Methods 0.000 claims description 3
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
230000000968 intestinal effect Effects 0.000 claims description 3
229910052751 metal Inorganic materials 0.000 claims description 3
239000002184 metal Substances 0.000 claims description 3
208000000689 peptic esophagitis Diseases 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
230000033764 rhythmic process Effects 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
230000002861 ventricular Effects 0.000 claims description 3
206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
239000004593 Epoxy Substances 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
206010049418 Sudden Cardiac Death Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
229910052744 lithium Inorganic materials 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
150000003458 sulfonic acid derivatives Chemical class 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
208000003663 ventricular fibrillation Diseases 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
206010003662 Atrial flutter Diseases 0.000 claims 2
206010042434 Sudden death Diseases 0.000 claims 1
208000008131 Ventricular Flutter Diseases 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
239000002904 solvent Substances 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 13
230000009471 action Effects 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
239000000243 solution Substances 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000002585 base Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
230000037396 body weight Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
108091006146 Channels Proteins 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
239000003416 antiarrhythmic agent Substances 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 5
239000000969 carrier Substances 0.000 description 5
AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229940082627 class iii antiarrhythmics Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
125000004356 hydroxy functional group Chemical group O* 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000003288 anthiarrhythmic effect Effects 0.000 description 3
210000004413 cardiac myocyte Anatomy 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
230000026030 halogenation Effects 0.000 description 3
238000005658 halogenation reaction Methods 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
210000000287 oocyte Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
241000269370 Xenopus <genus> Species 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000004442 acylamino group Chemical group 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 2
229960002994 dofetilide Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000008282 halocarbons Chemical class 0.000 description 2
150000004679 hydroxides Chemical class 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
PHFFZLIQGNLRRH-BYEGLACWSA-N 1-[(e)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]imidazolidine-2,4-dione;dihydrochloride Chemical compound Cl.Cl.C1CN(CCO)CCN1CCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O PHFFZLIQGNLRRH-BYEGLACWSA-N 0.000 description 1
MREBEPTUUMTTIA-XYGWBWBKSA-N 1-[(z)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C/C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-XYGWBWBKSA-N 0.000 description 1
MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 1
FEAVXMPFTQROEI-UHFFFAOYSA-N 2h-pyrano[3,2-b]pyridine Chemical class C1=CN=C2C=CCOC2=C1 FEAVXMPFTQROEI-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229940123073 Angiotensin antagonist Drugs 0.000 description 1
MREBEPTUUMTTIA-PCLIKHOPSA-N Azimilide Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-PCLIKHOPSA-N 0.000 description 1
BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
241000282412 Homo Species 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
208000018452 Torsade de pointes Diseases 0.000 description 1
208000002363 Torsades de Pointes Diseases 0.000 description 1
WKNIDMJWLWUOMZ-UHFFFAOYSA-N [K].[Cr] Chemical compound [K].[Cr] WKNIDMJWLWUOMZ-UHFFFAOYSA-N 0.000 description 1
ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
150000001346 alkyl aryl ethers Chemical group 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000002369 angiotensin antagonist Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
238000006172 aromatic nitration reaction Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229950001786 azimilide Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
235000011116 calcium hydroxide Nutrition 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
150000001983 dialkylethers Chemical class 0.000 description 1
229940082657 digitalis glycosides Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000003804 effect on potassium Effects 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
239000007789 gas Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
150000002440 hydroxy compounds Chemical class 0.000 description 1
230000002102 hyperpolarization Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
150000004701 malic acid derivatives Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
QSPPRYLTQFCUCH-UHFFFAOYSA-N n-methylethanesulfonamide Chemical compound CCS(=O)(=O)NC QSPPRYLTQFCUCH-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000001451 organic peroxides Chemical class 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
230000009090 positive inotropic effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000002336 repolarization Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000018556 stomach disease Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

HR19747889.1A 1997-08-05 1998-08-03 Sulphonamide-substituted compounds, process for their production and their use as medicaments or diagnostics as well as medicaments containing them HRP980426A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19733779A DE19733779A1 (de)	1997-08-05	1997-08-05	Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE1997147889 DE19747889A1 (de)	1997-10-30	1997-10-30	Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number	Publication Date
HRP980426A2 true HRP980426A2 (en)	1999-04-30

Family

ID=26038867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR19747889.1A HRP980426A2 (en)	1997-08-05	1998-08-03	Sulphonamide-substituted compounds, process for their production and their use as medicaments or diagnostics as well as medicaments containing them

Country Status (20)

Country	Link
US (1)	US6184221B1 (id)
EP (1)	EP0895994A3 (id)
JP (1)	JPH11100382A (id)
KR (1)	KR19990023304A (id)
CN (1)	CN1207391A (id)
AR (1)	AR015140A1 (id)
AU (1)	AU742918B2 (id)
BR (1)	BR9803739A (id)
CA (1)	CA2244577A1 (id)
CZ (1)	CZ243598A3 (id)
HR (1)	HRP980426A2 (id)
HU (1)	HUP9801789A3 (id)
ID (1)	ID20718A (id)
IL (1)	IL125642A (id)
NO (1)	NO983577L (id)
NZ (1)	NZ331230A (id)
PL (1)	PL327849A1 (id)
SK (1)	SK104298A3 (id)
TR (1)	TR199801492A3 (id)
TW (1)	TW526200B (id)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2341678C (en) *	1998-09-01	2009-10-13	Bristol-Myers Squibb Company	Potassium channel inhibitors and method
GB0315950D0 (en) *	2003-06-11	2003-08-13	Xention Discovery Ltd	Compounds
EP1879899B1 (en) *	2004-12-09	2010-08-04	Xention Limited	Thienopyridine derivatives as potassium channel inhibitors
US7576212B2 (en) *	2004-12-09	2009-08-18	Xention Limited	Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) *	2005-12-09	2006-01-18	Xention Discovery Ltd	Compounds
US7999107B2 (en)	2007-01-31	2011-08-16	Merck Sharp & Dohme Corp.	Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3008360C2 (de)	1980-03-05	1982-04-22	Chemische Werke Hüls AG, 4370 Marl	Verwendung von Copolyestern als Schmelzkleber zur Kantenverleimung
NZ230711A (en) *	1988-09-23	1990-10-26	Ortho Pharma Corp	Substituted thienopyrans as antihypertensive agents
US5428031A (en)	1991-12-03	1995-06-27	Merck & Co., Inc.	Methods of treating cardiac arrhythmia
TW496866B (en) *	1996-05-15	2002-08-01	Hoechst Ag	Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them
DE19706675A1 (de) *	1997-02-20	1998-08-27	Hoechst Ag	Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

1998
- 1998-07-30 EP EP98114307A patent/EP0895994A3/de not_active Withdrawn
- 1998-08-03 AR ARP980103831A patent/AR015140A1/es unknown
- 1998-08-03 KR KR1019980031470A patent/KR19990023304A/ko not_active Withdrawn
- 1998-08-03 IL IL12564298A patent/IL125642A/en not_active IP Right Cessation
- 1998-08-03 TW TW087112714A patent/TW526200B/zh active
- 1998-08-03 SK SK1042-98A patent/SK104298A3/sk unknown
- 1998-08-03 NZ NZ331230A patent/NZ331230A/en unknown
- 1998-08-03 ID IDP981070A patent/ID20718A/id unknown
- 1998-08-03 TR TR1998/01492A patent/TR199801492A3/tr unknown
- 1998-08-03 CZ CZ982435A patent/CZ243598A3/cs unknown
- 1998-08-03 HR HR19747889.1A patent/HRP980426A2/hr not_active Application Discontinuation
- 1998-08-04 BR BR9803739A patent/BR9803739A/pt not_active IP Right Cessation
- 1998-08-04 CA CA002244577A patent/CA2244577A1/en not_active Abandoned
- 1998-08-04 AU AU78661/98A patent/AU742918B2/en not_active Ceased
- 1998-08-04 JP JP10220387A patent/JPH11100382A/ja not_active Withdrawn
- 1998-08-04 US US09/128,664 patent/US6184221B1/en not_active Expired - Fee Related
- 1998-08-04 HU HU9801789A patent/HUP9801789A3/hu unknown
- 1998-08-04 CN CN98116752A patent/CN1207391A/zh active Pending
- 1998-08-04 NO NO983577A patent/NO983577L/no unknown
- 1998-08-05 PL PL98327849A patent/PL327849A1/xx unknown

Also Published As

Publication number	Publication date
ID20718A (id)	1999-02-18
KR19990023304A (ko)	1999-03-25
HUP9801789A3 (en)	2001-02-28
IL125642A0 (en)	1999-04-11
CA2244577A1 (en)	1999-02-05
EP0895994A3 (de)	1999-12-15
TW526200B (en)	2003-04-01
TR199801492A2 (xx)	1999-02-22
IL125642A (en)	2002-11-10
EP0895994A2 (de)	1999-02-10
PL327849A1 (en)	1999-02-15
CZ243598A3 (cs)	1999-02-17
AR015140A1 (es)	2001-04-18
NO983577D0 (no)	1998-08-04
AU7866198A (en)	1999-02-18
TR199801492A3 (tr)	1999-02-22
HUP9801789A2 (hu)	1999-09-28
CN1207391A (zh)	1999-02-10
HU9801789D0 (en)	1998-09-28
SK104298A3 (en)	1999-02-11
NZ331230A (en)	2000-06-23
BR9803739A (pt)	2000-03-21
AU742918B2 (en)	2002-01-17
JPH11100382A (ja)	1999-04-13
NO983577L (no)	1999-02-08
US6184221B1 (en)	2001-02-06

Legal Events

Date	Code	Title	Description
1999-04-30	A1OB	Publication of a patent application
1999-10-27	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2001-03-20	PNAN	Change of the applicant name, address/residence	Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, DE
2008-02-18	ODBI	Application refused

Publication	Publication Date	Title
SK283837B6 (sk)	2004-03-02	Chrómany, spôsob ich prípravy, liečivá, ktoré ich obsahujú, a ich použitie
HRP980086A2 (en)	1998-10-31	Sulfonamido substituted chromanes, processes for the preparation thereof, their use as medicines or diagnostic agents, as well as pharmaceutical preparations containing them
AU742918B2 (en)	2002-01-17	Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
HRP980098A2 (en)	1998-12-31	Sulfonamido substituted condensed, seven-membered ring compounds, their use as medicines and pharmaceutical preparations containing them
HRP980528A2 (en)	1999-06-30	Sulfonamid-substituted chromanes, process for their preparation, their use as medicaments, and pharmaceutical preparations containing them
AU727216B2 (en)	2000-12-07	Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
KR19990045147A (ko)	1999-06-25	설폰아미드-치환된 융합된 5원 환 화합물, 약제로서의 이의용도 및 이를 포함하는 약제학적 제제
JP4317601B2 (ja)	2009-08-19	スルホンアミド−置換された化合物、それらの製法、医薬または診断薬としてのそれらの使用およびそれらを含有する医薬製剤
MXPA98006267A (en)	1999-04-27	Substituted compounds with sulfonamide, procedure for its preparation, its use as a diagnostic medicine or agent as well as a medicine that contains them
HK1017680A (en)	1999-11-26	Sulfonamide-substituted compounds, processes for their prepartion, their use as a medicament oder diagnostic, and medicament comprising them
MXPA98001121A (en)	1998-11-12	Compositions replaced with sulfonamide, procedure for its preparation, its employment as a diagnostic medicine or agent as well as a medicine that conti
DE19747889A1 (de)	1999-05-06	Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19733779A1 (de)	1999-02-11	Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
MXPA97010126A (en)	1998-11-09	Substituted compounds with sulfonamide, procedure for preparation, employment as a medicine or diagnostic agent, as well as pharmaceutical preparations that contain them
MXPA98009370A (en)	1999-06-01	Condensed compounds with 5 members ring, substituted with sulfonamide, its use comomedicamentos, as well as pharmaceutical preparations that contains them
WO1998037083A1 (de)	1998-08-27	Sulfonamid-substituierte thiophene, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
DE19652213A1 (de)	1998-06-18	Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19730326A1 (de)	1999-01-21	Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen